Study and treatment of post XXXX (STOP-LD): a randomized double masked clinical trial.

@entity1 @entity2756 @entity3001 @entity1295 @entity281 @entity2841
OBJECTIVE: To determine whether @entity3001 ( @entity3001 ) is antibiotic responsive. METHODS: The authors conducted a single-center randomized double-masked placebo-controlled trial on 55 @entity1 with @entity3001 with persistent severe @entity1295 at least 6 or more months after antibiotic therapy. @entity1 were randomly assigned to receive 28 days of IV @entity2756 or placebo. The primary clinical outcomes were improvement in @entity1295 , defined by a change of 0.7 points or more on an 11-item @entity1295 questionnaire, and improvement in cognitive function (mental speed), defined by a change of 25% or more on a test of reaction time. The primary laboratory outcome was an experimental measure of @entity2841 @entity281 , outer surface protein A (OspA). Outcome data were collected at the 6-month visit. RESULTS: @entity1 assigned to @entity2756 showed improvement in disabling @entity1295 compared to the placebo group (rate ratio, 3.5; 95% CI, 1.50 to 8.03; p = 0.001). No beneficial treatment effect was observed for cognitive function or the laboratory measure of persistent @entity281 . Four @entity1 , three of whom were on placebo, had adverse events associated with treatment, which required hospitalization. CONCLUSIONS: @entity2756 therapy in @entity1 with @entity3001 with severe @entity1295 was associated with an improvement in @entity1295 but not with cognitive function or an experimental laboratory measure of @entity281 in this study. Because @entity1295 (a nonspecific symptom) was the only outcome that improved and because treatment was associated with adverse events, this study does not support the use of additional antibiotic therapy with parenteral @entity2756 in post-treatment, persistently @entity1295 @entity1 with @entity3001 .
